Carevive Systems receives Series C backing from Philips Improving outcomes for people with cancer isn’t only about breakthrough treatments — it also hinges on understanding the true patient experience in order to find ways to improve it. That’s the mission of Miami-based Carevive Systems, which recently received Series C backing from Philips. Carevive aims to enable providers to deliver better quality cancer care, encourages patient engagement and improves access to new treatments. Providers use Carevive software embedded within their EMR workflows to generate personalized patient care plans — based on the best possible treatment choices — and to remotely monitor and manage patient symptoms at home. “Carevive’s suite of patient engagement and clinical cancer care management technologies are very promising and we look forward to working with the company to further improve patient care,” says Rich Wilmot, managing director of investments at Philips Ventures.
By clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
I understandYou are about to visit a Philips global content page
ContinueBy clicking on the link, you will be leaving the official Royal Philips ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.
I understandYou are about to visit a Philips global content page
ContinueSelect country/region
Iraq (English)Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.